So it has been interesting the past couple days in the market. There was a lot of buying to end March but I think most saw that as the 60/40 (stock/bond) funds rebalancing. In other words, the move in the markets with stocks crashing and bonds flying meant that the 60/40 funds needed to sell […]
March 31st Biotech Update
A decent amount to talk about (some good some not so good). Yesterday I talked a little about the potential for the bottom to be in and data from China is actually supportive of that thesis. The PMI both bounced back in March and were better than expected. To be fair, a positive PMI survey […]
March 30th Biotech Update
The market continues higher albeit at a slower pace. Clearly the epidemic is not getting any better so why is the market holding up relative well? First, it could simply be the dead cat bounce from oversold conditions. I suspect that most think that is the likely scenario and that is not necessarily wrong. Second, […]
March 27th Biotech Update
Today is going to be an interesting day. The news has not been good this week but the market has had a nice recovery. I would expect that the news does not get any better this week and Boris Johnson has actually tested positive for COVID. We open lower and it seems setup well for […]
March 25th Biotech Update
I am still trying to get setup at home. I order a new desktop because I cannot stand writing on a laptop (I know I am a grumpy old man already). In any case, I will try and get more notes out on this laptop even though it drives me a little crazy typing on […]
March 17 Biotech Update
Do we get our turn around Tuesday? Timing is about right in terms of the oversold conditions and that they are almost historically oversold. A true dead cat bounce would be absolutely epic in the short squeeze. I am not talk a couple of percent or even 5%. When the bounce happens it should be […]
March 16th Biotech Update
It seems like the market and country is starting to come to terms with the scale of the epidemic and its economic impact but the trend remains until it is broken. The trend is crash at this point. I will be putting stink bids in trying to catch flash crashes as I still think those […]
March 12 Biotech Update
Was going to do the chat but it seemed to not work. Will perhaps try again tomorrow. I am sure bandwidth right now on the interest is not great as demand has increased. In any case, my bearish lean has unfortunately been accurate. All of the negatives for the market remain. The President had an […]
March 11 Biotech Update
We remain in a macro world but even that remains difficult to trade. The large intra-day moves puts pressure on trades as it could hit stop-loss levels or convince you that the trade is moving too far away from you. In addition, the administration is talking about stimulus and help but it cannot help everyone. […]
March 10th Biotech Update
We open green, which I am not sure is the best to start a counter trend rally. Keep in mind that with volatility this high, a 3% move is not actually that big or meaningful. Usually one would see a 3% move in a day as a strong signal but at these levels of volatility, […]
March 9th Biotech Update
We remain in a macro world with the twin barrels of COVID and an oil price war hitting the market. This is the first time this entire selloff that I sense there is real panic. That being said I still think we entire a bear market which would be $271 on the SPY but keep […]
March 6th Biotech Update
We remain (obviously) in a macro market and that means correlations remain very high. Interesting that today the sector seems to be a relative outperformer and seems to be the case this week. The sector is probably one of the least exposed to the economic impacts (at least at first), so it is not surprising […]
March 4th Biotech Update
Who would have thought that a Joe Biden Super Tuesday victory would cure the corona virus? The market is rallying on the election as it seems to put Biden back in as the democrat frontrunner. I suspect that the market would strongly prefer Biden over Sanders as the economy and market actually did pretty well […]
March 2nd Biotech Update
It seems like this week is setup for a nice counter trend rally. We might actually get a face ripping rally. Why? While the virus continues to spread, a lot of spread is now priced into expectations. The market is oversold. We are likely to see continued spread but nothing to put the epidemic to […]
February 25 Biotech Update
Today will be interesting for the markets. As I noted, the market has trained most to buy the dips and big sell-offs are followed by new highs. The gap up this morning could all but confirm that we are no longer in that type of market. If the gap turns into a gap and go, […]
February 24th Biotech Update
As I have been saying COVID risk will re-enter the market when (if) it expands outside of China and we now have 4 potential non-China epidemics in the works with Japan, South Korea, Italy and Iran. The weekend did not see any of these potential risks decrease and so we open the week lower. Traders […]
June 14 Biotech Update
It is Friday again, so be on the lookout for those rumors or late day runners. A slow start to the morning in terms of price action but we are basically trading with the market (although the IBB showing some small relative strength compared to SPY and XBI). 1. There is an interesting contrast with […]
Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 6
Proposed solution and conclusion Finally, I’d like to draw some conclusions and offer a different solution. First of all, it is clear that the corporate tax structure is way too complicated. Its provisions seem to be more focused on assuring tax revenue instead of focusing on economic efficiency and keeping America competitive in the international […]
Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 5
Proposed Policy Actions to curtail inversions All policy actions taken so far have been attempts at adjusting the tax code to greatly discourage inversion, but falls short of eliminating the incentive to invert. The Congressional Budget Office points to three policy options that are being considered for passage: Move significantly toward a purely worldwide system […]
Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 4
The incentives to invert Now that we have determined that inversions are not in America’s best interest and that multinational corporations are now actively seeking to invert, we must critically consider how to stop inversions. However, it is prudent to first understand the full scope of the incentives to invert. Results have shown that inversion […]
